Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Votrient“
Suchtreffer
Begriffe & Kennungen
Votrient
Eintrag öffnenVotrient · 4.1 Therapeutic indications · 1
Eintrag öffnenVotrient · 4.3 Contraindications · 1
Eintrag öffnenVotrient · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenVotrient · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenVotrient · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenVotrient · 4.5 · 8 once daily alone. Some patients however may have systemic pazopanib exposure greater than what has been obse
Eintrag öffnenVotrient · 4.5 · 9 Pazopanib is an inhibitor of the uridine diphosphoglucuronosyl-transferase 1A1 (UGT1A1) enzyme in vitro. The
Eintrag öffnenVotrient · 4.5 · Administration of 1500 mg lapatinib (a substrate for and weak inhibitor of CYP3A4 and P-gp and a potent inhibi
Eintrag öffnenVotrient · 4.5 · Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold increase in AUC
Eintrag öffnenVotrient · 4.5 · Based on in vitro IC50 and in vivo plasma Cmax values, pazopanib metabolites GSK1268992 and GSK1268997 may con
Eintrag öffnenVotrient · 4.5 · CYP3A4, P-gp, BCRP inducers CYP3A4 inducers such as rifampin may decrease plasma pazopanib concentrations. Co-
Eintrag öffnenVotrient · 4.5 · CYP3A4, P-gp, BCRP inhibitors Pazopanib is a substrate for CYP3A4, P-gp and BCRP.
Eintrag öffnenVotrient · 4.5 · Co-administration of pazopanib with a CYP3A4, P-gp, and BCRP inhibitor, such as lapatinib, will result in an i
Eintrag öffnenVotrient · 4.5 · Co-administration of pazopanib with other strong inhibitors of the CYP3A4 family (e.g. itraconazole, clarithro
Eintrag öffnenVotrient · 4.5 · Combination with strong P-gp or BCRP inhibitors should be avoided, or selection of an alternate concomitant me
Eintrag öffnenVotrient · 4.5 · Concomitant administration of pazopanib with esomeprazole decreases the bioavailability of pazopanib by approx
Eintrag öffnenVotrient · 4.5 · Concomitant use of pazopanib and simvastatin increases the incidence of ALT elevations. Results from a meta-an
Eintrag öffnenVotrient · 4.5 · Concomitant use of pazopanib with a strong CYP3A4 inhibitor should be avoided (see section 4.4). If no medical
Eintrag öffnenVotrient · 4.5 · Concurrent administration of pazopanib (400 mg once daily) with the strong CYP3A4 and P-gp inhibitor ketoconaz
Eintrag öffnen